Protein identified as TIM 3 that turns off HIV-fighting T cells in HIV positive patients sufferring from AIDS. – In HIV-infected patients the body’s immune system is unable to fight off the virus. A new study to be published online on November 10th in the Journal of Experimental Medicine shows that T cells in HIV-infected individuals express a protein called TIM-3, which inactivates their virus killing capacity.
Study suggests HIV infected patients should start highly active antiretroviral therapy (HAART) sooner. – Under current treatment guidelines, highly active antiretroviral therapy (HAART) should be considered for HIV-infected patients when their CD4+ T-cell counts fall below 350 cells per cubic millimeter (mm3).
Researchers from the Harvard School of Public Health (HSPH) estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa. – More than 330,000 lives were lost to HIV/AIDS in South Africa from 2000 and 2005 because a feasible and timely antiretroviral (ARV) treatment program was not implemented, assert researchers from the Harvard School of Public Health (HSPH) in a study published online by the Journal of Acquired Immune Deficiency Syndromes (JAIDS) (http://www.jaids.com/).
Antiretroviral therapy with TB treatment for HIV patients reduces mortality up to fifty five percent. – A South African treatment study conducted by researchers in the Department of Epidemiology at the Mailman School of Public Health shows that mortality among TB-HIV co-infected patients can be reduced by a remarkable 55%, if antiretroviral therapy (ART) is provided with TB treatment at the same time.
UA-led research indicates the HIV/AIDS pandemic began around 1900 in sub-Saharan Africa, decades earlier than first thought – New research indicates that the most pervasive global strain of HIV began spreading among humans between 1884 and 1924, suggesting that growing urbanization in colonial Africa set the stage for the HIV/AIDS pandemic.
Only 1% of people living with HIV/AIDS worldwide have been screened for tuberculosis, according to a report recently released by the coalition Advocacy To Control TB Internationally, or ACTION. – A mere 1% of people living with HIV/AIDS are reported to have been screened for TB, according to the most recent global data available from the World Health Organization. Health experts and activists at the International AIDS Conference are calling upon HIV/AIDS programs and international donors to ensure universal TB screening of every person who has tested positive for HIV.
The availability of new antiretroviral drugs and formulations, including drugs in new classes, and recent data on treatment choices for antiretroviral-naive and -experienced patients warrant an update of the International AIDS Society?USA guidelines for the use of antiretroviral therapy in adult human immunodeficiency virus (HIV) infection. – An evaluation of recent data has led to an update in the guidelines and recommendations for antiretroviral treatment of adult human immunodeficiency virus (HIV) infection, according to an article in the August 6 issue of JAMA, a theme issue on HIV/AIDS.
When clinicians use simple physical signs of deteriorating health — such as weight loss or fever — these doctors can provide therapies almost as effective as those relying on the most advanced laboratory analysis. – When millions of HIV-infected people in poor countries began receiving advanced drug therapies, critics worried that patient care would suffer because few high-tech laboratories were available to guide treatments. But according to a study being published in The Lancet, these concerns are as yet unfounded.
Even with effective anti-HIV therapies, doctors still have not been able to eradicate the virus from infected individuals who are receiving such treatments, largely because of the persistence of HIV in hideouts known as viral reservoirs. – HIV virus is not usually eradicated from infected individuals even after long term HIV therapy because of the persistence of HIV in hideouts known as viral reservoirs. One important reservoir is the gut, where HIV causes much of its damage due to the large number of HIV target cells that reside there.
The U.S. Food and Drug Administration approved etravirine tablets for the treatment of HIV infection in adults who have failed treatment with other antiretrovirals. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that helps to block an enzyme which HIV needs to multiply. – US FDA approved Tibotec Therapeutics’ Intelence, etravirine tablets for the treatment of HIV infection, to be used in combination with other anti-HIV medications, in adults who have failed treatment with other antiretrovirals.
Brazil facing significant challenges with the rising cost of providing universal access to HIV/AIDS treatment. – AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries (or 25% of those in need in developing countries) receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as “AIDS cocktails.”
